Anti-inflammatory and Anti-platelet effect of Clopidogrel and Aspirin vs Aspirin alone in Symptomatic Polyvascular disease and in patients with multiple recurrent cardiovascular events. - ND

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI0 个研究点开始时间: 2008年9月22日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Patients of both sexes, between 40 and 75 years of age and with symptomatic polyvascular disease or recurrent cardiovascular events will be included. In particular inclusion criteria include patients with established stable coronary artery disease (no
•acute coronary events in the 6 months before study entry with one of the following condition: stable angina with documented multivessels coronary disease, history of multivessel percutaneous coronary intervention, history of multivessel coronary artery bypass grafting or previous MI) associated with peripheral disease (current intermittent claudication and ankle-brachial index0,85 or history of intermittent claudication with previous leg amputation, reconstructive surgery , or angioplasty) or cerebrovascular disease ( a previous documented TIA or Stroke) and patients with more than two acute cardiovascular events ( examples: more than 2 MI,or 2 MI plus one TIA or stroke).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•The major exclusion criteria include cronic treatment with oral anticoagulant and other antiplatelet drugs wich might rise the emorragic risk; intollerance/allergy to aspirin or clopidrogrel; platelet count < 125 >145 10 ^/L;
•other exclusion criteria are inflammatory or infectious disease, malignancies, or immunologic or hematologic disorders.

发起方

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI